Latest Conference Articles

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens discusses some of the ways that Walgreens is advancing care for patients with cancer.

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens, talks about the growing role of specialty pharmacies in delivering cancer care.

It was during the middle of the night when Suzanne Soliman, PharmD, founder of the Pharmacist Mom Group on Facebook, got the idea for her group page, which has since grown to be one of the most active on the popular social media platform, with more than 2 million posts last year alone.

At the Asembia Specialty Pharmacy Summit 2019, Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens discussed top trends in specialty pharmacy that are likely to continue to impact the industry.

During the featured session at Asembia’s Specialty Pharmacy Summit 2019, “Specialty Industry Outlook: What’s Next,” speakers Adam Fein, PhD, CEO of the Drug Channels Institute; Lisa Gill, managing director of J.P. Morgan Securities; and Doug Long, vice president of industry relations at IQVIA, explored the radical changes that could be on the horizon from potential legislation that would dramatically alter the health care industry.

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens provided insight into new areas of technology that pharmacists can use to help improve care when treating patients with cancer.

Matt Farber, MA, Senior Director of Patient Care and Advocacy at Walgreens, discussed the role of specialty pharmacists in working to manage the cost burden of cancer care.

Since the growth of specialty pharmacies, genetically acquired bleeding disorders such as von Willebrand disease (VWD) have been among the most common conditions addressed at these practice locations.

At the Asembia Specialty Pharmacy Summit 2019, Scott Gottlieb, MD, 23rd commissioner of the FDA discussed the agency's role in rewriting the modern rules of new regulatory paradigms for a number of recent advancements in medicine.

The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovation in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at the Asembia Specialty Pharmacy Summit 2019.

Co-pay accumulator programs are the latest cost management initiative resulting from the constant push and pull between payers, pharmacy benefit managers, and manufacturers to reduce drug spend.

Treatment for inflammatory bowel disease has the best outcomes when patients partner with their medical teams.

Why health system specialty pharmacies are uniquely positioned to provide valuable data and superior care to the patients they serve.

The specialty lite platform leverages the current infrastructure of specialty pharmacies with efficient services and emerging technological solutions that focus on ensuring prescription fulfillment with economic feasibility.

Experts emphasized the need for clinicians to use every available tool when patients need PCSK9 inhibitors but face access barriers.

During a session on Monday at Asembia’s Specialty Pharmacy Summit 2019, experts discussed specialty pharmacy’s potential to improve outcomes for patients with pulmonary arterial hypertension.

Diagnostic delay tends to be a challenge for patients with hereditary angioedema, a rare but serious condition affecting 1 in 50,000 individuals.

During the week of the summit, you’ll find shows unique to the city that are sure to make lifelong memories.

This new offering provides an end-to-end digital prescription process with nationwide access through more than 25,000 retail pharmacies.

Check back daily for our coverage of the Asembia Specialty Pharmacy Summit this week.

What considerations should pharmacists keep in mind when treating patients with chronic lymphocytic leukemia?

Bernard Marini, PharmD, BCOP, gives an overview of selecting the most effective, safest, and most cost-effective acute myeloid leukemia treatments for patients.

The high cost of targeted treatments for acute myeloid leukemia has made it difficult for patients to access these therapies.

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut discusses key trials in prostate cancer research.

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, discussed the recent updates to the American Cancer Society's screening guidelines for colorectal cancer.

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, provides an overview of the evolving treatment paradigm for chronic lymphocytic leukemia.

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, discusses the importance of the pharmacist's role in the management of chronic lymphocytic leukemia treatments.

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, explains how pharmacists can counsel patients about risk factors for colorectal cancer and reduction strategies.